Article
MZE829 Well-tolerated with Dose-proportional Pharmacokinetics Supporting Once Daily Dosing Data Support Advancement of MZE829 into Planned Phase 2 Clinical Trial in Patients with AKD Data Presented Today at the American Society of Nephrology Kidney Week 2024 Excerpt from the Press Release: SOUTH SAN FRANCISCO, CA., October 25, 2024 – Maze Therapeutics, a clinical-stage biopharmaceutical company…
Read More
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits (-91%, p=0.001), All Cause Office Visits (-41%, p=0.027) and All Cause Hospital Outpatient Visits (-89%, p=0.032) within 6-month index period Data presented at American…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., Oct. 28, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for…
Read More
Excerpt from the Press Release: LOS GATOS, Calif., Oct. 27, 2024 /PRNewswire/ — Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today the successful first-in-human use of its novel interatrial shunt in patients with heart failure. The initial cases were performed by George Khabeishvili, MD, at Tbilisi Heart…
Read More
Excerpt from the Press Release: SAN DIEGO and AUSTIN, Texas and HAMILTON, ON, Oct. 15, 2024 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the publication of a peer-reviewed article titled “Preclinical development…
Read More
Novel SEQ SIFTER™ discovery platform used to re-engineer original human IgE antibodies into IgG antibodies to block binding and protect against peanut allergen Topline data expected in mid-2025 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 /PRNewswire/ — IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune mediated diseases,…
Read More
-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection – – New pharmacokinetic data provides further evidence of the RaniPill platform’s potential to enable oral delivery of multiple obesity treatments – – Phase 1 study for RT-114, an oral…
Read More
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumab Patients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months); 22 months in KRAS mutant population…
Read More
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Excerpt from the Press Release: BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE)…
Read More
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn’s selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) —…
Read More